Mechanistic Insights into Melatonin's Antiarrhythmic Effects in Acute Ischemia-Reperfusion-Injured Rabbit Hearts Undergoing Therapeutic Hypothermia

Int J Mol Sci. 2025 Jan 13;26(2):615. doi: 10.3390/ijms26020615.

Abstract

The electrophysiological mechanisms underlying melatonin's actions and the electrophysiological consequences of superimposed therapeutic hypothermia (TH) in preventing cardiac ischemia-reperfusion (IR) injury-induced arrhythmias remain largely unknown. This study aimed to unveil these issues using acute IR-injured hearts. Rabbits were divided into heart failure (HF), HF+melatonin, control, and control+melatonin groups. HF was induced by rapid right ventricular pacing. Melatonin was administered orally (10 mg/kg/day) for four weeks, and IR was created by 60-min coronary artery ligation and 30-min reperfusion. The hearts were then excised and Langendorff-perfused for optical mapping studies at normothermia, followed by TH. Melatonin significantly reduced ventricular fibrillation (VF) maintenance. In failing hearts, melatonin reduced the spatially discordant alternans (SDA) inducibility mainly by modulating intracellular Ca2+ dynamics via upregulation of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) and calsequestrin 2 and attenuating the downregulation of phosphorylated phospholamban protein expression. In control hearts, melatonin improved conduction slowing and reduced dispersion of action potential duration (APDdispersion) by upregulating phosphorylated connexin 43, attenuating the downregulation of SERCA2a and phosphorylated phospholamban and attenuating the upregulation of phosphorylated Ca2+/calmodulin-dependent protein kinase II. TH significantly retarded intracellular Ca2+ decay slowed conduction, and increased APDdispersion, thereby facilitating SDA induction, which counteracted the beneficial effects of melatonin in reducing VF maintenance.

Keywords: electrophysiology; ischemia-reperfusion injury; melatonin; therapeutic hypothermia; ventricular fibrillation.

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Anti-Arrhythmia Agents / therapeutic use
  • Arrhythmias, Cardiac / drug therapy
  • Arrhythmias, Cardiac / etiology
  • Arrhythmias, Cardiac / metabolism
  • Calcium / metabolism
  • Connexin 43 / metabolism
  • Disease Models, Animal
  • Heart Failure / drug therapy
  • Heart Failure / etiology
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Hypothermia, Induced* / methods
  • Male
  • Melatonin* / pharmacology
  • Myocardial Reperfusion Injury* / drug therapy
  • Myocardial Reperfusion Injury* / metabolism
  • Rabbits
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
  • Ventricular Fibrillation / drug therapy
  • Ventricular Fibrillation / metabolism

Substances

  • Melatonin
  • Anti-Arrhythmia Agents
  • Calcium
  • Connexin 43
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases